Latest news for Aareal Bank (OTC:AABKF) Stock

Aareal Bank AG is the parent company of the Aareal Bank Group, an international purveyor of financing services that specializes in commercial property financing. The group's companies are organized into three business segments: structured property financing Banking and Digital solutions and Aareon. Its segment includes the Structured property financing segment, the group serves its customers' projects in Europe, North America, and Asia. The banking and digital solutions segment offers its clients from the institutional housing industry and commercial property companies. Its Aareon segment offers property management systems supplied. The majority of the bank's new financing opportunities take place in Western Europe.

Aareal Bank AG

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) with a Buy and maintains $30 price target.

News

Price Target

Reiteration

Analyst Ratings

ADXN

HC Wainwright & Co. Reiterates Buy on Addex Therapeutics, Maintains $30 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju downgrades Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) from Buy to Neutral.

Downgrades

HC Wainwright & Co. Downgrades Kezar Life Sciences to Neutral

VERA

Vera Therapeutics To Present Long-term Results From Origin Phase 2B Clinical Trial Of Atacicept For Treatment Of IgAN

Biotech

Health Care

General

GNTA

The Agenzia Italiana del Farmaco Has Approved Genenta Science's New Phase 1 Trial For Metastatic Renal Cell Cancer For Genenta's Flagship Product, Temferon

This program is expected to build on the positive data reported to date from the ongoing ORIGIN Phase 2b and 3 clinical program developing atacicept to treat patients with IgAN, by extending into a broader population of IgAN and other autoimmune kidney indications.

Vera Therapeutics Reports Expansion Of Its Development Pipeline For Its Lead Asset, Atacicept

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) with a Buy and maintains $43 price target.

BBIO

HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $43 Price Target

Needham analyst Mayank Tandon reiterates Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) with a Hold.

LPRO

Needham Reiterates Hold on Open Lending

CORRECTION: Redwire Announced It Is Providing A Critical Onboard Computer System For The European Space Agency's Hera Mission, Europe's Inaugural Flagship Planetary Defense Mission

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Buy and maintains $52 price target.

HRMY

Needham Reiterates Buy on Harmony Biosciences, Maintains $52 Price Target

Needham analyst Scott Berg reiterates SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) with a Buy and maintains $18 price target.

SEMR

Needham Reiterates Buy on SEMrush Hldgs, Maintains $18 Price Target

HC Wainwright &amp; Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) with a Buy and maintains $10 price target.

PRME

HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $10 Price Target

As part of its expansion, YY Circle, the Group&#39;s flagship interactive job-matching platform, will now be available to employers and job seekers in the UK&#39;s hospitality, retail, and service sectors. These industries, which have been navigating labor shortages and operational challenges, stand to benefit from YY Circle&#39;s intelligent workforce management solutions.

YYGH

YY Group Holding Reveals Its Expansion Into The UK Market

HC Wainwright &amp; Co. analyst Edward White initiates coverage on Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) with a Buy rating and announces Price Target of $15.

Initiation

Larimar Therapeutics, Inc. - Common Stock

LRMR

HC Wainwright & Co. Initiates Coverage On Larimar Therapeutics with Buy Rating, Announces Price Target of $15

<a href="https://digital-strategy.ec.europa.eu/en/news/commission-sends-requests-information-youtube-snapchat-and-tiktok-recommender-systems-under-digital" title="https://digital-strategy.ec.europa.eu/en/news/commission-sends-requests-information-youtube-snapchat-and-tiktok-recommender-systems-under-digital">https://digital-strategy.ec.europa.eu/en/news/commission-sends-requests-information-youtube-snapchat-and-tiktok-recommender-systems-under-digital</a>

Tech

GOOG

GOOGL

SNAP

EU Commission Sends Requests For Information To YouTube, Snapchat, TikTok On Recommender Systems Under Digital Services Act

Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) has reportedly launched a new AI chatbot named &#8220;Cedric,&#8221; designed to be safer than ChatGPT created by OpenAI for internal use.
What Happened: The internal document obtained by Business Insider describes Cedric as a &#8220;general purpose AI chatbot&#8221; that can assist employees with tasks such as asking questions, summarizing documents, and brainstorming ideas. This tool aims to boost productivity and job satisfaction among Amazon employees, Business Insider <a href="https://www.businessinsider.in/artificial-intelligence/news/amazon-quietly-rolled-out-a-new-ai-chatbot-that-is-safer-than-chatgpt-for-employees-to-use/articleshow/113860733.cms">reported</a> on Tuesday.
Amazon has been cautious about using third-party AI tools like ChatGPT due to security concerns. The company formalized guidelines earlier this year to ban external AI tools for business purposes. Cedric is part of Amazon&#8217;s effort to provide a secure alternative.
According to the internal document, Cedric was developed using Amazon&#8217;s Bedrock AI platform and Anthropic&#8217;s Claude large language model. It is designed to handle highly confidential data securely, with chat history saved in an encrypted database.
See Also: <a href="https://www.benzinga.com/news/24/10/41111038/elon-musk-gets-bold-font-removed-from-xs-main-timeline-because-of-excessive-use-my-eyes-are-bleeding?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Gets Bold Font Removed From X&#8217;s Main Timeline Because Of &#8216;Excessive&#8217; Use: &#8216;My Eyes Are Bleeding&#8217;</a>
Amazon employees are encouraged to use Cedric for creating memos, turning meeting notes into emails, and generating new ideas. However, for code generation, employees should use Amazon Q instead of Cedric.
Amazon has yet to respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> queries.
Why It Matters: Amazon&#8217;s introduction of Cedric follows its ongoing efforts to enhance AI capabilities internally. Earlier this year, Amazon was reported to be working on a <a href="https://www.benzinga.com/markets/equities/24/06/39470396/amazon-set-to-challenge-chatgpt-parent-openai-with-new-ai-service-metis-report">new AI chatbot,</a> codenamed Metis, designed to compete with OpenAI's ChatGPT. Metis aims to provide real-time information and automate tasks using a technique called retrieval-augmented generation.
Additionally, Amazon has been leveraging AI to <a href="https://www.benzinga.com/news/24/06/39529418/amazon-leverages-ai-to-aid-in-finance-operations-and-improve-analyses">improve its finance operations</a>. The company has integrated generative AI into its finance teams to assist with complex analyses, moving beyond traditional rules-based systems and machine learning. 
Previously, CEO Andy Jassy also highlighted the significant amount of work hours that have been saved by their generative artificial <a href="https://www.benzinga.com/markets/equities/24/08/40524790/amazon-ceo-andy-jassy-says-companys-ai-assistant-has-saved-260m-and-4-5k-developer-years-of-work">intelligence assistant, Amazon Q</a>. Calling it a &#8220;game changer,&#8221; Jassy noted that Amazon Q&#8217;s efficiency is equivalent to &#8220;4,500 developer-years of work.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41087287/elon-musk-responds-after-y-combinators-paul-graham-says-twitter-name-change-was-a-waste-of-time-you?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Responds After Y Combinator&#8217;s Paul Graham Says Twitter Name Change &#8216;Was A Waste Of Time:&#8217; &#8216;You Know Nothing&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

AMZN

Amazon Reportedly Urges Employees To Use In-House AI Chatbot 'Safer' Than ChatGPT

HC Wainwright &amp; Co. analyst Heiko Ihle maintains US Goldmining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USGO#NASDAQ">USGO</a>) with a Buy and raises the price target from $23.5 to $24.

USGO

HC Wainwright & Co. Maintains Buy on US Goldmining, Raises Price Target to $24

Earnings

MLEC

Moolec Science Q4 2024 GAAP EPS $(0.07) Misses $(0.06) Estimate, Sales $1.523M Beat $1.255M Estimate

HC Wainwright &amp; Co. analyst Scott Buck reiterates Super League Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) with a Buy and maintains $3 price target.

HC Wainwright & Co. Reiterates Buy on Super League Enterprise, Maintains $3 Price Target

Target Announced The Release Of Its 2024 Bullseye's Top Toys List, Which Includes More Than 60 Toys, Nearly Half Of Which Are Exclusive To Target

The ELA provides Comstock IP Holdings with the exclusive worldwide right to use the NREL technologies in the processing and conversion of seed plants to renewable fuels and renewable fuel feedstocks, including native, hybrid, and transgenic phenotypes, and derivatives thereof, excluding switchgrass, big bluestem, miscanthus, and the leaves, stalks, and husks produced during the harvesting of corn, subject to limited geographic restrictions, in exchange for royalty and other fees linked to sales of licensed products and sublicensing.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Aareal Bank

News

Latest news for Aareal Bank (OTC:AABKF) Stock